MedTrace Logo

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003646 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2011-07-07

No results posted yet for this study

Summary

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Conditions

  • Stage IV Melanoma
  • Stage III Melanoma
  • Recurrent Melanoma

Interventions

DRUG

allovectin-7

Sponsors & Collaborators

  • Vical

    lead INDUSTRY

Principal Investigators

  • Jennifer Fernandez · Vical

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2002-03-31
Completion
2002-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003646 on ClinicalTrials.gov